Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...

Ocugen (OCGN) announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa ...

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...

The fact that differentiation between classic and occult CNV and the recognition of the lesion components was not established until later on in the course of macular photocoagulation trials may ...

Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...

The aim of this treatment was to destroy the CNV in order to preserve macular function ... appropriate for the majority of subfoveal lesions and for juxtafoveal CNV while at this moment we ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has unveiled encouraging preliminary data from the Phase 1 portion of its OCU410 ...